Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism

Sima Halevy; Hani Giryes; Ilana Avinoach; Ella Livni; Shaul Sukenik

doi:10.1016/S0926-9959(97)00114-1

Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism

Sima Halevy
, Hani Giryes
, Ilana Avinoach
, Ella Livni
, Shaul Sukenik

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

The rare occurrence of methotrexate (MTX)-induced vasculitis has been associated mainly with high or intermediate MTX doses. We report herein a case of cutaneous leukocytoclastic vasculitis (LCV) following treatment with low-dose oral MTX (7.5 mg/week) for rheumatoid arthritis. The histological findings of a cutaneous lesion were consistent with drug-induced vasculitis. The clinical and histological findings, including the temporal relationship between MTX intake and the onset of vasculitis, and the results of withdrawal and rechallenge tests, suggest a causal relationship, and indicate a drug- induced LCV due to MTX. The role of MTX in the induction of the vasculitis was further supported by a positive mast cell degranulation (MCD) test.

Original language	English
Pages (from-to)	81-85
Number of pages	5
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1016/S0926-9959(97)00114-1
State	Published - 27 Feb 1998

Keywords

Leukocytoclastic vasculitis
Mast cell degranulation test
Methotrexate

ASJC Scopus subject areas

Dermatology
Infectious Diseases

Access to Document

10.1016/S0926-9959(97)00114-1

Cite this

@article{06a1a9d4b82749dc879ef178c6f685e5,

title = "Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism",

abstract = "The rare occurrence of methotrexate (MTX)-induced vasculitis has been associated mainly with high or intermediate MTX doses. We report herein a case of cutaneous leukocytoclastic vasculitis (LCV) following treatment with low-dose oral MTX (7.5 mg/week) for rheumatoid arthritis. The histological findings of a cutaneous lesion were consistent with drug-induced vasculitis. The clinical and histological findings, including the temporal relationship between MTX intake and the onset of vasculitis, and the results of withdrawal and rechallenge tests, suggest a causal relationship, and indicate a drug- induced LCV due to MTX. The role of MTX in the induction of the vasculitis was further supported by a positive mast cell degranulation (MCD) test.",

keywords = "Leukocytoclastic vasculitis, Mast cell degranulation test, Methotrexate",

author = "Sima Halevy and Hani Giryes and Ilana Avinoach and Ella Livni and Shaul Sukenik",

year = "1998",

month = feb,

day = "27",

doi = "10.1016/S0926-9959(97)00114-1",

language = "English",

volume = "10",

pages = "81--85",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Leukocytoclastic vasculitis induced by low-dose methotrexate

T2 - In vitro evidence for an immunologic mechanism

AU - Halevy, Sima

AU - Giryes, Hani

AU - Avinoach, Ilana

AU - Livni, Ella

AU - Sukenik, Shaul

PY - 1998/2/27

Y1 - 1998/2/27

N2 - The rare occurrence of methotrexate (MTX)-induced vasculitis has been associated mainly with high or intermediate MTX doses. We report herein a case of cutaneous leukocytoclastic vasculitis (LCV) following treatment with low-dose oral MTX (7.5 mg/week) for rheumatoid arthritis. The histological findings of a cutaneous lesion were consistent with drug-induced vasculitis. The clinical and histological findings, including the temporal relationship between MTX intake and the onset of vasculitis, and the results of withdrawal and rechallenge tests, suggest a causal relationship, and indicate a drug- induced LCV due to MTX. The role of MTX in the induction of the vasculitis was further supported by a positive mast cell degranulation (MCD) test.

AB - The rare occurrence of methotrexate (MTX)-induced vasculitis has been associated mainly with high or intermediate MTX doses. We report herein a case of cutaneous leukocytoclastic vasculitis (LCV) following treatment with low-dose oral MTX (7.5 mg/week) for rheumatoid arthritis. The histological findings of a cutaneous lesion were consistent with drug-induced vasculitis. The clinical and histological findings, including the temporal relationship between MTX intake and the onset of vasculitis, and the results of withdrawal and rechallenge tests, suggest a causal relationship, and indicate a drug- induced LCV due to MTX. The role of MTX in the induction of the vasculitis was further supported by a positive mast cell degranulation (MCD) test.

KW - Leukocytoclastic vasculitis

KW - Mast cell degranulation test

KW - Methotrexate

UR - https://www.scopus.com/pages/publications/0031907326

U2 - 10.1016/S0926-9959(97)00114-1

DO - 10.1016/S0926-9959(97)00114-1

M3 - Article

AN - SCOPUS:0031907326

SN - 0926-9959

VL - 10

SP - 81

EP - 85

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 1

ER -

Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this